Expert Review of Anti-infective Therapy最新文献

From Data to Decisions: Leveraging Large, Real-World Databases to Guide Clinical Practice in C. difficile Infections. 从数据到决策：利用大型真实世界数据库来指导艰难梭菌感染的临床实践。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-31 DOI: 10.1080/14787210.2025.2541713

Kelly R Reveles, Kelsey A Strey

引用次数: 0

The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios. 亚太地区念珠菌种类的流行病学变化以及在具有挑战性的临床情况下优化抗真菌剂量的证据。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-31 DOI: 10.1080/14787210.2025.2539427

Yee-Chun Chen, Sohita Dhillon, Nicholas Adomakoh, Jason A Roberts

{"title":"The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.","authors":"Yee-Chun Chen, Sohita Dhillon, Nicholas Adomakoh, Jason A Roberts","doi":"10.1080/14787210.2025.2539427","DOIUrl":"https://doi.org/10.1080/14787210.2025.2539427","url":null,"abstract":"Introduction: The global burden of invasive fungal infections (IFIs) is increasing, with the threat of disease exacerbated by the emergence of antifungal resistance. While antifungals remain the mainstay for the treatment of IFIs, there is a growing recognition of many patient variables, particularly in challenging situations (e.g. critically ill patients) that can impact the exposure of antifungals.Areas covered: This narrative review focuses on the changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios, based on a symposium held at the International Society for Human and Animal Mycology Asia Congress in Bangkok, Thailand, on 1 August 2024.Expert opinion: Antifungal resistance is common and increasing among fungal pathogens (e.g. Candida species) in the Asia Pacific. Optimal drug selection and dosing of antifungals is critical for achieving the best therapeutic outcomes and limiting resistance emergence, particularly in challenging clinical scenarios. Current 'standard' doses of antifungals do not account for pharmacokinetic variations in critically ill patients and can lead to suboptimal exposures, highlighting the need for better dosing regimens in these patients. Therapeutic drug monitoring is a valuable strategy for optimizing antifungal therapy, and its use is encouraged, particularly in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":3.8,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Penile microbiomes have important implications for HIV susceptibility and broader reproductive health. 阴茎微生物组对艾滋病毒易感性和更广泛的生殖健康具有重要意义。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-29 DOI: 10.1080/14787210.2025.2541712

Rameen Jamil, Jessica L Prodger, Ronald M Galiwango, Cindy M Liu, Aaron A R Tobian, Rupert Kaul

引用次数: 0

Clinical, scientific and healthcare system consequences of misdiagnosing neonatal sepsis. 误诊新生儿败血症的临床、科学和卫生保健系统后果。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-29 DOI: 10.1080/14787210.2025.2538612

Constantin R Popescu, Pascal M Lavoie

{"title":"Clinical, scientific and healthcare system consequences of misdiagnosing neonatal sepsis.","authors":"Constantin R Popescu, Pascal M Lavoie","doi":"10.1080/14787210.2025.2538612","DOIUrl":"10.1080/14787210.2025.2538612","url":null,"abstract":"Introduction: Neonatal sepsis remains a major contributor to morbidity and mortality worldwide, with the highest burden in low- and middle-income countries (LMICs). Generating accurate estimates of disease burden is critical for setting research priorities, informing health policy, and resource allocation. However, in many LMICs, limited access to timely and reliable diagnostic tools severely limits case detection, undermines epidemiological surveillance, and impedes efforts to improve clinical outcomes.Areas covered: This review examines the clinical, scientific, and health system implications of misdiagnosing neonatal sepsis. We describe the challenges of accurate case identification and summarize findings from prospective, multicenter studies showing marked variability in incidence across different geographic and healthcare settings. We explore the sources of this variability and discuss its impact on patient care, clinical trials interpretation, and progress toward reducing the global burden of neonatal sepsis.Expert opinion: The lack of standardized case definition hinders neonatal sepsis research and may contribute to the growing threat of antimicrobial resistance. Addressing this requires acknowledging the substantial uncertainty in current global incidence estimates. More importantly, it demands shifting focus from passive reporting of variability to actively investigating the methodological, sociodemographic, clinical, biological, and systemic drivers that shape sepsis detection and outcomes across diverse settings.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":3.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and controversies in the diagnosis and management of neurocysticercosis: a clinical perspective. 神经囊虫病诊断与治疗的进展与争议：临床观点。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-28 DOI: 10.1080/14787210.2025.2536825

Tissiana Marques de Haes, Thales Pardini Fagundes, Osvaldo Massaiti Takayanagui

{"title":"Advances and controversies in the diagnosis and management of neurocysticercosis: a clinical perspective.","authors":"Tissiana Marques de Haes, Thales Pardini Fagundes, Osvaldo Massaiti Takayanagui","doi":"10.1080/14787210.2025.2536825","DOIUrl":"10.1080/14787210.2025.2536825","url":null,"abstract":"Introduction: Neurocysticercosis remains the leading parasitic infection of the human central nervous system and a primary cause of epilepsy in low- and middle-income regions. Although advances in magnetic resonance imaging, serologic assays, and antiparasitic regimens have improved disease recognition and lesion targeting, major clinical questions remain unresolved regarding optimal diagnosis and management.Areas covered: This Perspective critically reviews current diagnostic and therapeutic approaches in neurocysticercosis, emphasizing the role of high-resolution imaging and evolving immunologic tools. The literature search methodology included searches of PubMed and Google Scholar databases, focusing on publications related to neurocysticercosis diagnosis, clinical manifestations, treatment, and public health interventions. It discusses treatment selection based on cyst location, stage, and host immune profile, and explores the evidence supporting albendazole and praziquantel in parenchymal, ventricular, subarachnoid, and disseminated forms. Pediatric, pregnant, and immunocompromised patients are examined as distinct clinical populations.Expert opinion: The management of neurocysticercosis demands individualized, lesion-specific strategies rather than uniform protocols. While advances in imaging and immunotherapy hold promise, implementation barriers persist in endemic areas. Future priorities include robust randomized trials for extraparenchymal disease, validation of immunologic biomarkers, and integrated public health measures to reduce the disease burden globally.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":3.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prescriber knowledge, behaviour and attitudes regarding antibiotic use and antibiotic resistance in Oman. 阿曼开处方者关于抗生素使用和抗生素耐药性的知识、行为和态度。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-28 DOI: 10.1080/14787210.2025.2538613

Zainab Said Al-Hashimy, Barbara R Conway, Sayer Al-Azzam, Reema Karasneh, Said Saud Al Harthi, Stuart E Bond, Mamoon A Aldeyab

{"title":"Prescriber knowledge, behaviour and attitudes regarding antibiotic use and antibiotic resistance in Oman.","authors":"Zainab Said Al-Hashimy, Barbara R Conway, Sayer Al-Azzam, Reema Karasneh, Said Saud Al Harthi, Stuart E Bond, Mamoon A Aldeyab","doi":"10.1080/14787210.2025.2538613","DOIUrl":"10.1080/14787210.2025.2538613","url":null,"abstract":"Background: Antimicrobial resistance threatens patients, healthcare systems, and the world's economy. Antimicrobial stewardship programs use evidence-based strategies to monitor and assess antibiotic use. This study aimed to identify prescribers' knowledge, attitudes, and behavior regarding antibiotic use and antibiotic resistance in Oman.Research design and methods: A cross-sectional study was conducted using a questionnaire that was adapted from the European Centre for Disease Prevention and Control instruments. The survey was distributed among prescribers in Oman's Ministry of Health.Results: The survey included a total of 371 prescribers. Most respondents were specialists, and 73% worked in hospitals. Antibiotics' effectiveness against viruses, needless use, and adverse effects were accurately answered by over 95% of prescribers. Eighty-four percent of prescribers realized the connection between their prescribing of antibiotics and the spread of antibiotic-resistant bacteria. Approximately 80% agreed that they address antibiotic resistance and consider it when treating patients. Around 70% of prescribers knew of the Oman national action plan to combat antibiotic resistance. Sixty-six percent of prescribers wanted information regarding antibiotic resistance, 49% about antibiotic use, and 40% about antibiotic prescriptions and medical problems.Conclusion: The findings highlight the need for interventions to inform prescriber knowledge and behavior, improve antibiotic prescribing practices, and combat the spread of antimicrobial resistance.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":4.2,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimicrobial management of complex biofilms in diabetic foot ulcers: a microbiological perspective. 糖尿病足溃疡复杂生物膜的抗菌管理：微生物学观点。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-25 DOI: 10.1080/14787210.2025.2538614

Manuela Oliveira, Eva Cunha, Luís Tavares, Isa Serrano

{"title":"Antimicrobial management of complex biofilms in diabetic foot ulcers: a microbiological perspective.","authors":"Manuela Oliveira, Eva Cunha, Luís Tavares, Isa Serrano","doi":"10.1080/14787210.2025.2538614","DOIUrl":"10.1080/14787210.2025.2538614","url":null,"abstract":"Introduction: Diabetic foot ulcers (DFUs) are a significant health concern, often complicated by biofilm formation which delays healing and increases the risk of diabetic foot infections (DFIs). Effective management of complex biofilms is crucial for improving patient outcomes and reducing the risk of amputation and premature death.Areas covered: This review summarizes the current state of microbiological research on DFIs, focusing on bacterial populations, biofilm interactions, and their role in antibiotic resistance development, being based on a PubMed search from 1975 to 2025. It also explores recent advances in antimicrobial therapies, including phage therapy, antimicrobial peptides, and other novel treatments.Expert opinion: Antimicrobial stewardship, broader access to medical resources, and improved sanitation are essential to diminish the impact of diabetes on healthcare systems. Furthermore, the development of a rapid tool to detect antibiotic-tolerant cells is fundamental to avoid DFIs relapse. The biofilms dynamics and the dual relationship between biofilms and the immune system should be further understood. While traditional antibiotics are essential to treat DFIs, a multi-combinatorial strategy combining conventional compounds with alternative therapies should be more effective to overcome resistance and promote wound healing in DFUs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":4.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical treatment of mycobacterial prosthetic joint infections. 分枝杆菌假体关节感染的临床治疗：现有病例的文献回顾。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-24 DOI: 10.1080/14787210.2025.2536837

Cristina Ortega-Portas, Alvaro Auñon, Jaime Esteban

{"title":"Clinical treatment of mycobacterial prosthetic joint infections.","authors":"Cristina Ortega-Portas, Alvaro Auñon, Jaime Esteban","doi":"10.1080/14787210.2025.2536837","DOIUrl":"10.1080/14787210.2025.2536837","url":null,"abstract":"Introduction: Prosthetic joint infections (PJIs) caused by mycobacteria are exceptionally rare and often underrecognized in clinical practice.Areas covered: Although most PJIs are due to common bacterial pathogens, Mycobacterium tuberculosis and nontuberculous mycobacteria (NTM) represent a unique subset with distinct microbiological and therapeutic challenges. The presence of biofilms further complicates their management, often requiring intensive pharmacological interventions and surgical strategies. This review analyzes over 300 reported cases of mycobacterial PJIs. The findings indicate that tuberculous PJIs typically occur as late-onset infections and are managed successfully with prolonged antituberculous therapy. In contrast, NTM PJIs - predominantly caused by rapidly growing species - are more heterogeneous in onset, resistance patterns, and treatment responses. Antibiotic regimens are often complex, species-specific, and require guidance from susceptibility testing. Therapeutic decisions often rely on expert consensus and extrapolation from pulmonary disease protocols. Surgical intervention, particularly implant removal, consistently correlates with better outcomes in both groups.Expert opinion: Clinicians must maintain a high index of suspicion in culture-negative PJIs or cases with atypical clinical presentations to reach a proper diagnosis. Once the diagnosis is established, a multidisciplinary approach is crucial for optimizing patient outcomes. Further research is warranted to develop evidence-based strategies for these rare but clinically demanding infections.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Naegleria fowleri: emerging therapies and translational challenges. 福氏奈格里氏菌：新兴疗法和转化挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-23 DOI: 10.1080/14787210.2025.2536827

Ruqaiyyah Siddiqui, Sutherland K Maciver, Naveed Ahmed Khan

{"title":"Naegleria fowleri: emerging therapies and translational challenges.","authors":"Ruqaiyyah Siddiqui, Sutherland K Maciver, Naveed Ahmed Khan","doi":"10.1080/14787210.2025.2536827","DOIUrl":"https://doi.org/10.1080/14787210.2025.2536827","url":null,"abstract":"Introduction: Naegleria fowleriis a rare but fatal free-living amoeba with > 97% mortality rate. Despiteadvances in clinical and scientific understanding, therapeutic options remainlimited, and diagnosis is often delayed, presenting significant public healthchallenges.Areas covered: We reviewed recent literature fromthe last decade, using Google scholar and PubMed on N. fowleri treatment, emerging drugcandidates, repurposed therapeutics, and innovative delivery strategies.Advancements in drug screening are highlighted, unveiling novel therapeutictargets and mechanisms of action. Additionally, the role of climate change andenvironmental factors in geographic expansion and increased incidence ofinfections is explored, posing a growing public health risk.Expert opinion: Effective managementof N. fowleri infections hinges on early detection and addressingresearch gaps, particularly in understanding transmission/disease mechanisms. Recentadvances in therapeutics, diagnostics, and water treatment to reduceenvironmental contamination by N. fowleri show promise for loweringinfection risk and improving outcomes for primary amoebic meningoencephalitis. Collaborationamong academic institutions, pharmaceutical companies, and water industries isessential, with research advancing treatments and vaccines, and waterindustries contributing by reducing environmental contamination/human exposureto N. fowleri. A combination of treatment strategies and stringentsurveillance will be crucial to limit future outbreaks and improve patientprognosis.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brincidofovir in the Era of Mpox. Brincidofovir在m痘时代。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-20 DOI: 10.1080/14787210.2025.2532029

James McCarty, David Cassie, Shantha Kodihalli, Efe Aigbedo, Jing Tian, Kevin Yeo, Vanja Komlenovic, Lovelyn Charles, Bojan Drobic, Bob Warnock

{"title":"Brincidofovir in the Era of Mpox.","authors":"James McCarty, David Cassie, Shantha Kodihalli, Efe Aigbedo, Jing Tian, Kevin Yeo, Vanja Komlenovic, Lovelyn Charles, Bojan Drobic, Bob Warnock","doi":"10.1080/14787210.2025.2532029","DOIUrl":"10.1080/14787210.2025.2532029","url":null,"abstract":"Introduction: Mpox (formerly monkeypox), a systemic infection caused by the mpox virus (MPXV), has become a global problem of increasing concern. There are currently no antiviral treatments that have been shown to be safe and effective for the treatment of mpox.Areas covered: Brincidofovir is a lipid-modified acyclic nucleotide with in vitro and in vivo activity against multiple DNA viruses, including MPXV. It is licensed in the US and Canada for the treatment of human smallpox disease in adults and children, including neonates. It has been used under FDA-authorized emergency use for patients in the US with severe mpox. The authors review the antiviral activity, clinical development, pharmacokinetics, safety and efficacy of brincidofovir and its potential as an mpox treatment. A comprehensive review was conducted in PubMed, Science Direct, Embase and Google Scholar.Expert opinion: Research is needed to better understand mpox epidemiology, natural history, antiviral therapy and vaccines. Brincidofovir is being evaluated in a randomized, double-blind, placebo-controlled trial under the Mpox Study in Africa (MOSA) protocol. Additional studies will assist in clarification of single vs. combination therapy, safety and populations most likely to benefit, as well as the management of treatment complications such as immune reconstitution inflammatory syndrome (IRIS).","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-16"},"PeriodicalIF":4.2,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0